These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

224 related items for PubMed ID: 20699068

  • 1. [Therapeutic drug monitoring of 6-thioguanine nucleotides in inflammatory bowel disease: interest and limits].
    Jourdil N, Fonrose X, Boulieu R, Stanke-Labesque F, Suivi Thérapeutique Pharmacologique de la Société Française de Pharmacologie et de Thérapeutique.
    Therapie; 2010; 65(3):177-86. PubMed ID: 20699068
    [Abstract] [Full Text] [Related]

  • 2. [Not Available].
    Jourdil N, Fonrose X, Boulieu R, Stanke-Labesque F, pour le groupe Suivi Thérapeutique Pharmacologique de la Société Française de Pharmacologie et de Thérapeutique.
    Therapie; 2010; 65(3):177-86. PubMed ID: 27392984
    [Abstract] [Full Text] [Related]

  • 3. Review article: the benefits of pharmacogenetics for improving thiopurine therapy in inflammatory bowel disease.
    Chouchana L, Narjoz C, Beaune P, Loriot MA, Roblin X.
    Aliment Pharmacol Ther; 2012 Jan; 35(1):15-36. PubMed ID: 22050052
    [Abstract] [Full Text] [Related]

  • 4. Thiopurine methyltransferase activity combined with 6-thioguanine metabolite levels predicts clinical response to thiopurines in patients with inflammatory bowel disease.
    Kwan LY, Devlin SM, Mirocha JM, Papadakis KA.
    Dig Liver Dis; 2008 Jun; 40(6):425-32. PubMed ID: 18304898
    [Abstract] [Full Text] [Related]

  • 5. Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease.
    Gearry RB, Barclay ML.
    J Gastroenterol Hepatol; 2005 Aug; 20(8):1149-57. PubMed ID: 16048561
    [Abstract] [Full Text] [Related]

  • 6. Monitoring of long-term thiopurine therapy among adults with inflammatory bowel disease.
    Hindorf U, Lyrenäs E, Nilsson A, Schmiegelow K.
    Scand J Gastroenterol; 2004 Nov; 39(11):1105-12. PubMed ID: 15545169
    [Abstract] [Full Text] [Related]

  • 7. Thiopurine methyl-transferase activity and azathioprine metabolite concentrations do not predict clinical outcome in thiopurine-treated inflammatory bowel disease patients.
    González-Lama Y, Bermejo F, López-Sanromán A, García-Sánchez V, Esteve M, Cabriada JL, McNicholl AG, Pajares R, Casellas F, Merino O, Carpio D, Vera MI, Muñoz C, Calvo M, Benito LM, Bujanda L, García-Fernández FJ, Ricart E, Ginard D, Velasco M, Carneros JA, Manceñido N, Calvo M, Algaba A, Froilan C, Cara C, Maté J, Abreu L, Gisbert JP, "Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU)".
    Aliment Pharmacol Ther; 2011 Sep; 34(5):544-54. PubMed ID: 21722149
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Review article: thiopurines in inflammatory bowel disease.
    Derijks LJ, Gilissen LP, Hooymans PM, Hommes DW.
    Aliment Pharmacol Ther; 2006 Sep 01; 24(5):715-29. PubMed ID: 16918876
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Monitoring of azathioprine metabolites in pediatric patients with autoimmune hepatitis.
    Nguyen TM, Daubard M, Le Gall C, Larger M, Lachaux A, Boulieu R.
    Ther Drug Monit; 2010 Aug 01; 32(4):433-7. PubMed ID: 20479703
    [Abstract] [Full Text] [Related]

  • 12. A 6-thioguanine nucleotide threshold level of 400 pmol/8 x 10(8) erythrocytes predicts azathioprine refractoriness in patients with inflammatory bowel disease and normal TPMT activity.
    Roblin X, Peyrin-Biroulet L, Phelip JM, Nancey S, Flourie B.
    Am J Gastroenterol; 2008 Dec 01; 103(12):3115-22. PubMed ID: 19086961
    [Abstract] [Full Text] [Related]

  • 13. [Therapy of chronic inflammatory bowel diseases with azathioprine, 6-mercaptopurine and 6-thioguanine. Clinico-pharmacologic aspects].
    Schwab M, Herrlinger K, Schaeffeler E, Stange EF.
    Dtsch Med Wochenschr; 2003 Feb 21; 128(8):378-85. PubMed ID: 12594624
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Thioguanine-nucleotides do not predict efficacy of tioguanine in Crohn's disease.
    Herrlinger KR, Fellermann K, Fischer C, Kreisel W, Deibert P, Schoelmerich J, Fleig WE, Ruhl A, Reinshagen M, Greinwald R, Stange EF, Schwab M.
    Aliment Pharmacol Ther; 2004 Jun 15; 19(12):1269-76. PubMed ID: 15191508
    [Abstract] [Full Text] [Related]

  • 16. Monitoring 6-thioguanine nucleotide concentrations in Japanese patients with inflammatory bowel disease.
    Andoh A, Tsujikawa T, Ban H, Hashimoto T, Bamba S, Ogawa A, Sasaki M, Saito Y, Fujiyama Y.
    J Gastroenterol Hepatol; 2008 Sep 15; 23(9):1373-7. PubMed ID: 18662197
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Cost-effectiveness of thiopurine methyltransferase genotype screening in patients about to commence azathioprine therapy for treatment of inflammatory bowel disease.
    Winter J, Walker A, Shapiro D, Gaffney D, Spooner RJ, Mills PR.
    Aliment Pharmacol Ther; 2004 Sep 15; 20(6):593-9. PubMed ID: 15352906
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.